NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Clinical trials for NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) explained in plain language.
Never miss a new study
Get alerted when new NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) trials appear
Sign up with your email to follow new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowThis early-phase study tests a new treatment called HBI0101 CAR T for people with severe autoimmune diseases like lupus, multiple sclerosis, and rheumatoid arthritis that haven't improved with standard treatments. The therapy uses a patient's own immune cells, modified to target …
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated May 26, 2026 11:22 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called QH103 in up to 6 people with relapsed or hard-to-treat autoimmune diseases like multiple sclerosis and myasthenia gravis. The therapy uses specially engineered immune cells to target and calm the overactive immune system. The…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New study tracks ultomiris safety in pregnant women
Knowledge-focused Recruiting nowThis study monitors 75 pregnant or postpartum women who have taken Ultomiris for conditions like PNH or aHUS. Researchers will track pregnancy outcomes and infant health up to one year after birth. The goal is to better understand any risks or complications linked to the drug dur…
Matched conditions: NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 26, 2026 11:27 UTC